About EndoGastric Solutions

Mission Statement

EndoGastric Solutions provides innovative, minimally invasive solutions that address unmet needs in gastrointestinal diseases. Our core focus has been on the significant and growing unmet need in the Gastroesophageal Reflux Disease (GERD) space, where caregivers lacked a durable minimally invasive, non-pharmaceutical long-term treatment option until our current EsophyX^® Z device using TIF 2.0^® procedure. GERD is one of the most common reasons why patients see primary care and/or GI physicians. Left untreated, GERD can develop into pain-inducing, potential life-threatening diseases. Our vision is to restore patients’ lives to life before they experienced GERD/Acid Reflux. Our employees are deeply committed to this primary objective and it shows in the key deliverables achieved across all functional departments. We consistently highlight how our work impacts the lives of millions of patients suffering from GERD, and have created a culture of collaboration, teamwork, and open communication to maximize our deliverables to caregivers focused on gastrointestinal diseases.

EndoGastric Solutions (EGS) is a medical device company focused on developing and commercializing innovative, evidence-based, non-invasive surgical technology for the treatment of gastroesophageal reflux disease (GERD).

EndoGastric Solutions has become a leader in incisionless procedural therapy for GERD.
Our mission is to combine the most advanced concepts in gastroenterology and surgery to develop products and procedures that address unmet needs in gastrointestinal diseases.

EGS’ proprietary technology platform, the EsophyX® fastener delivery system, is designed to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids refluxing back into the esophagus. EGS is committed to further developing and commercializing innovative, evidence-based, incisionless surgical technology.

The original EsophyX® device and SerosaFuse® fasteners were CE marked in 2006 and cleared by the FDA in 2007. The technology has continued to evolve with the launch of the company’s third, third generation device, the EsophyX Z+ device in 2017. The device is commercially available in the United States and numerous other OUS countries, and used by both gastroenterologists and surgeons to treat GERD.

The EsophyX device is used to perform the company’s TIF® procedure (Transoral Incisionless Fundoplication)—a surgical solution performed without the need for external incisions through the skin that enables physicians to reconstruct the gastroesophageal valve from within the stomach and correct the root cause of GERD.

NP02613-01B